Source: Blood. Conference titles: 65th ASH Annual Meeting Abstracts. Unidades: FM, ICB, FMRP
Subjects: FARMACOLOGIA, HEMATOLOGIA, LEUCEMIA MIELOIDE AGUDA, QUIMIOTERAPIA COMBINADA, CÉLULAS CULTIVADAS DE TUMOR, PROLIFERAÇÃO CELULAR, NEOPLASIAS POR TIPO HISTOLÓGICO, ANTINEOPLÁSICOS, PROTEÍNAS, CÉLULAS MIELOIDES
ABNT
LIMA, Keli Cristina de et al. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia. Blood, v. 142, n. Supl. 1, p. 5774, 2023Tradução . . Disponível em: https://doi.org/10.1182/blood-2023-189998. Acesso em: 09 nov. 2024.APA
Lima, K. C. de, Carvalho, M. F. L., Martins, D. A. P., Nascimento, M. C. do, Nogueira, F. L., Medeiros, R. de C. C., et al. (2023). Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia. Blood, 142( Supl. 1), 5774. doi:10.1182/blood-2023-189998NLM
Lima KC de, Carvalho MFL, Martins DAP, Nascimento MC do, Nogueira FL, Medeiros R de CC, Schuringa JJ, Rego EM, Machado Neto JA. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia [Internet]. Blood. 2023 ; 142( Supl. 1): 5774.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1182/blood-2023-189998Vancouver
Lima KC de, Carvalho MFL, Martins DAP, Nascimento MC do, Nogueira FL, Medeiros R de CC, Schuringa JJ, Rego EM, Machado Neto JA. Identification of vulnerabilities for pharmacological inhibition of PIP4K2s in Acute Myeloid Leukemia [Internet]. Blood. 2023 ; 142( Supl. 1): 5774.[citado 2024 nov. 09 ] Available from: https://doi.org/10.1182/blood-2023-189998